Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 20 Vitamin D Deficiency 17 Prostatic Neoplasms 14 Neoplasms 9 Polycystic Ovary Syndrome 8 Colonic Neoplasms 8 Rectal Neoplasms 6 Colorectal Neoplasms 6 Myelodysplastic Syndromes 5 Osteoporosis 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Cardiovascular Diseases 4 Warts 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Ovarian Neoplasms 3 Leukemia, Myeloid, Acute 3 Leukemia 3 Brain Neoplasms 3 Adenomatous Polyps 3 Pathologic Processes 2 Pain 2 Obesity 2 Myeloproliferative Disorders 2 Myelodysplastic-Myeloproliferative Diseases 2 Musculoskeletal Diseases 2 Melanoma 2 Male Urogenital Diseases 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2

Interventions

toripalimab 1 durvalumab 1 advexin 1 Surveys and Questionnaires 1 Sampling Studies 1 Nivolumab 1 Mitomycin 1 Mastectomy, Subcutaneous 1 Magnetic Resonance Imaging 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Cystoscopy 1 Cholecalciferol 1 Blood Specimen Collection 1 Biopsy 1 Aminolevulinic Acid 1 1-phenyl-3,3-dimethyltriazene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma in Situ × Cholecalciferol × Clear all

NCT02698293 2022-11-22

PDT Plus Vitamin D3 for Anal Dysplasia

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn

Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡